These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824 [TBL] [Abstract][Full Text] [Related]
5. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698 [TBL] [Abstract][Full Text] [Related]
6. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785 [TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231 [TBL] [Abstract][Full Text] [Related]
9. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112 [TBL] [Abstract][Full Text] [Related]
11. Genetic testing in Poland and Ukraine: should comprehensive germline testing of Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa. ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584 [TBL] [Abstract][Full Text] [Related]
14. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102 [TBL] [Abstract][Full Text] [Related]
15. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2). Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613 [TBL] [Abstract][Full Text] [Related]
16. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients. Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668 [TBL] [Abstract][Full Text] [Related]
17. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926 [TBL] [Abstract][Full Text] [Related]
18. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families. Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625 [TBL] [Abstract][Full Text] [Related]
20. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]